ClinicalTrials.gg
RecruitingNCT06793033ARISE RCTUpdated Nov 17, 2025

A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support

An interventional study of Advanced Cardiac Life Support (ACLS) and Aortic balloon occlusion (ABO) in Cardiac Arrest (CA) and Cardiopulmonary Arrest, sponsored by neurescue. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by neurescue · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Heart Arrest with a site in Germany — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Germany.

Planned enrollment
14th of 23
84 · median 150
Started
2025
with 2 others
No phase
18 of 38
4 open now
Registered
33rd of 38
by date
Lead sponsor
2 of 38
neurescue

Among the 38 studies in Heart Arrest with a site in Germany, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 18 with no phase, and was the 33rd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

8 of the 38 studies in Heart Arrest with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Heart Arrest with a site in Germany, or all of them as a file.
02

Study summary

The NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.

The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.

The purpose of this study is to compare the clinical safety and performance of Advanced Cardiovascular Life Support (ACLS) versus ACLS in combination with Aortic Balloon Occlusion (ABO) using the NEURESCUE device in subjects with cardiac arrest.

Read the detailed description

Subjects will be randomized into two arms: ACLS treatment or ACLS + ABO treatment. Those in the ACLS treatment arm will receive standard of care treatment for cardiac arrest, while those in Arm 2 will receive ACLS in combination with ABO.

The NEURESCUE device is an aortic balloon catheter designed to temporarily occlude the aorta. During the treatment, the NEURESCUE Catheter will be placed in the descending aorta and be connected to the NEURESCUE Assistant. The NEURESCUE Assistant facilitates pressure-regulated inflation and deflation of the balloon.

Throughout the treatment, cardiac rhythm and return of spontaneous circulation (ROSC) will be monitored.

The subject will be monitored for a total of 4 visits, where a 90-days follow-up will account for the last visit.

03

Conditions studied

  • Cardiac Arrest (CA)
  • Cardiopulmonary Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and ≤80 years
  • Witnessed arrest
  • CPR initiated within 7 min of arrest
  • CPR time less than 40 min at enrollment
  • Non-shockable rhythm

Exclusion criteria

Exclusion Criteria:

  • Traumatic cardiac arrest
  • Known pregnancy
  • Known terminal disease
  • Known do-not-attempt-CPR order
  • Known opposition to study participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (Control)

    Enrolled subjects randomized into Arm 1 will receive ACLS treatment.

    Procedure: Advanced Cardiac Life Support (ACLS)

  • Experimental
    Arm 2 (Intervention)

    Enrolled subjects randomized into Arm 2 will receive ACLS treatment combined with ABO.

    Procedure: Advanced Cardiac Life Support (ACLS) · Device: Aortic balloon occlusion (ABO)

Interventions

  • ProcedureAdvanced Cardiac Life Support (ACLS)

    Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.

  • DeviceAortic balloon occlusion (ABO)

    Aortic balloon occlusion (ABO) is a technique that diverts blood flow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest. In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest.

06

What researchers measure

Primary outcomes

  1. Resuscitation

    Subject achieving shockable rhythm or ROSC

    Time frame: Measured from 10 minutes after randomization to 70 minutes after randomization

Secondary outcomes

  1. Epinephrine

    Dosage of epinephrine administered during resuscitation

    Time frame: Measured from 10 minutes after randomization to 70 minutes after randomization

  2. Procedures

    Need for any invasive procedures, e.g. surgery, extracorporeal membrane oxygenation (ECMO) or percutaneous coronary intervention (PCI)

    Time frame: Measured from 10 minutes after randomization to 90 days post cardiac arrest

  3. (S)A(D)E

    All Anticipated (S)AEs/(S)ADEs and Unanticipated (S)AEs/(S)ADEs

    Time frame: Measured from randomization to 90 days post cardiac arrest

  4. CPC score

    Cerebral Performance Category (CPC) is a five-point scale used to categorize the neurological outcome after cardiac arrest

    Time frame: Measured at dischage or at 7 days post cardiac arrest, and 90 days post cardiac arrest

  5. EQ-5D

    EQ-5D is a standardized measure of quality of life

    Time frame: Measured 90 days post cardiac arrest

  6. Survival

    Survival at discharge or 7 day post cardiac arrest (whichever comes first), and survival at 90 days post cardiac arrest

    Time frame: Measured at dischage or at 7 days post cardiac arrest, and 90 days post cardiac arrest

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 219 interventional studies with no phase under Heart Arrest, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06793033
Lead sponsor
neurescue
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Jul 7, 2025
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Michael Preusch, M.D.
Contact
Michael.Preusch@med.uni-heidelberg.de
+49 151 40044669‬

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion